 Dexamethasone
"Dexamethasone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-inflammatory 9-fluoro-glucocorticoid.
| Descriptor ID |
D003907
|
| MeSH Number(s) |
D04.210.500.745.432.769.344 D04.210.500.908.238
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dexamethasone".
Below are MeSH descriptors whose meaning is more specific than "Dexamethasone".
This graph shows the total number of publications written about "Dexamethasone" by people in this website by year, and whether "Dexamethasone" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 2 | 4 | | 1996 | 4 | 2 | 6 | | 1997 | 2 | 3 | 5 | | 1998 | 1 | 3 | 4 | | 1999 | 1 | 5 | 6 | | 2000 | 2 | 3 | 5 | | 2001 | 4 | 2 | 6 | | 2002 | 0 | 2 | 2 | | 2003 | 6 | 1 | 7 | | 2004 | 1 | 1 | 2 | | 2005 | 1 | 2 | 3 | | 2006 | 3 | 2 | 5 | | 2007 | 1 | 3 | 4 | | 2008 | 4 | 3 | 7 | | 2009 | 1 | 3 | 4 | | 2010 | 4 | 2 | 6 | | 2011 | 1 | 9 | 10 | | 2012 | 8 | 6 | 14 | | 2013 | 2 | 4 | 6 | | 2014 | 2 | 8 | 10 | | 2015 | 5 | 2 | 7 | | 2016 | 1 | 4 | 5 | | 2017 | 5 | 4 | 9 | | 2018 | 1 | 4 | 5 | | 2019 | 10 | 2 | 12 | | 2020 | 3 | 9 | 12 | | 2021 | 3 | 6 | 9 | | 2022 | 1 | 9 | 10 | | 2023 | 2 | 8 | 10 | | 2024 | 4 | 4 | 8 | | 2025 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Dexamethasone" by people in Profiles.
-
Freyer DR, Ohlsen TJD, Don D, Orgel E, Hayashi RJ, Lieu JE, Foster JH, Sitton MS, Geller JI, Choo DI, Rangaswami A, Chang KW, Greffe B, Chan K, Lee A, Grunstein E, O'Neill AF, Rahbar R, Anderson JJ. Feasibility and Safety of Intratympanic Administration of Sustained-Exposure Dexamethasone Thermosensitive Gel (OTO-104) for Prevention of Cisplatin-Induced Hearing Loss in Children: A Multisite Phase 2 Randomized Clinical Trial. Pediatr Blood Cancer. 2025 Jun; 72(6):e31680.
-
Kant R, Mishra N, Kandhari K, Saba L, Tewari-Singh N, Petrash JM, Agarwal C, Agarwal R. Dexamethasone mitigates sulfur mustard-induced stem cell deficiency in vivo in rabbit limbal tissue by reducing inflammation and oxidative stress. Arch Toxicol. 2025 Apr; 99(4):1531-1543.
-
Kumar R, Nolan K, Kassa B, Chanana N, Palmo T, Sharma K, Singh K, Mickael C, Fonseca Balladares D, Nilsson J, Prabhakar A, Mishra A, Lee MH, Sanders L, Kumar S, Molofsky AB, Stenmark KR, Sheppard D, Tuder RM, Gupta MD, Thinlas T, Pasha Q, Graham BB. Monocytes and interstitial macrophages contribute to hypoxic pulmonary hypertension. J Clin Invest. 2025 Jan 30; 135(6).
-
Pimple SN, Pedler MG, Shieh B, Mandava A, McCourt E, Petrash JM. Human Breast Milk Enhances Cellular Proliferation in Cornea Wound Healing. Curr Eye Res. 2024 Nov; 49(11):1138-1144.
-
Nelipovich S, Vepraskas SH, Soung P, Pronko K, Yan K, Zhang L, Porada K, Chou E. Outcomes of a dexamethasone-prednisone combination treatment course for status asthmaticus. J Asthma. 2024 Dec; 61(12):1646-1654.
-
Derman BA, Cooperrider J, Rosenblatt J, Avigan DE, Rampurwala M, Barnidge D, Major A, Karrison T, Jiang K, Ramsland A, Kubicki T, Jakubowiak AJ. Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
-
Kubicki T, Jamroziak K, Robak P, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Wr?bel T, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Kruk-Kwapisz D, Derman BA, Major A, Jakubowiak AJ, Dytfeld D. Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone. Pol Arch Intern Med. 2024 05 28; 134(5).
-
Kant R, Mishra N, Kandhari K, Saba L, Michel C, Reisdorph R, Tewari-Singh N, Pantcheva MB, Petrash JM, Agarwal C, Agarwal R. Dexamethasone targets actin cytoskeleton signaling and inflammatory mediators to reverse sulfur mustard-induced toxicity in rabbit corneas. Toxicol Appl Pharmacol. 2024 02; 483:116834.
-
Mishra N, Kant R, Kandhari K, Tewari-Singh N, Anantharam P, Croutch CR, Pantcheva MB, Petrash JM, Araj H, Agarwal C, Agarwal R. Establishing a Dexamethasone Treatment Regimen To Alleviate Sulfur Mustard-Induced Corneal Injuries in a Rabbit Model. J Pharmacol Exp Ther. 2024 01 17; 388(2):469-483.
-
Mishra N, Kant R, Kandhari K, Ammar DA, Tewari-Singh N, Pantcheva MB, Petrash JM, Agarwal C, Agarwal R. Nitrogen Mustard-Induced Ex Vivo Human Cornea Injury Model and Therapeutic Intervention by Dexamethasone. J Pharmacol Exp Ther. 2024 01 17; 388(2):484-494.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|